According to research by Boughdad et al., [18F]FDG PET/CT may become a simple and affordable “surrogate marker” to track tumor response, particularly in post-menopausal women with ER-rich/HER2− BC who may benefit from NET therapy [58]. This evidence concerns the gene ESR1 and breast cancer.